Therapeutic potential of cannabidiol in depression

Matti Bock Guldager, Adriano Maia Chaves Filho, Caroline Biojone, Sâmia Joca*

*Corresponding author for this work

Research output: Contribution to book/anthology/report/proceedingBook chapterResearchpeer-review

Abstract

Major depressive disorder (MDD) is a widespread and debilitating condition affecting a significant portion of the global population. Traditional treatment for MDD has primarily involved drugs that increase brain monoamines by inhibiting their uptake or metabolism, which is the basis for the monoaminergic hypothesis of depression. However, these treatments are only partially effective, with many patients experiencing delayed responses, residual symptoms, or complete non-response, rendering the current view of the hypothesis as reductionist. Cannabidiol (CBD) has shown promising results in preclinical models and human studies. Its mechanism is not well-understood, but may involve monoamine and endocannabinoid signaling, control of neuroinflammation and enhanced neuroplasticity. This chapter will explore CBD's effects in preclinical and clinical studies, its molecular mechanisms, and its potential as a treatment for MDD.

Original languageEnglish
Title of host publicationCannabidiol in Neurology and Psychiatry
Number of pages43
Place of publicationLondon
PublisherAcademic Press
Publication dateJan 2024
Pages251-293
Chapter11
ISBN (Print)978-0-443-23591-7
DOIs
Publication statusPublished - Jan 2024
SeriesInternational Review of Neurobiology
Volume177
ISSN0074-7742

Keywords

  • Antidepressant
  • Glutamate
  • Monoamines
  • Neuroplasticity
  • Neurotransmitter
  • Stress

Fingerprint

Dive into the research topics of 'Therapeutic potential of cannabidiol in depression'. Together they form a unique fingerprint.

Cite this